Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 2/20 | 0.47 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CCR6 | P51684 | 3/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31155643 | 0.85 | CNR1 (0.49) | JAK2FPR2PROKR1CNR1CCR6 | |
| SCHEMBL31155589 | 0.85 | EPHX2 (0.51) | JAK2FPR2PROKR1CNR1CCR6 | |
| SCHEMBL32670649 | 0.84 | JAK2 (0.43) | JAK2FPR2PROKR1CNR1CCR6 | |
| SCHEMBL26461273 | 0.82 | CCR6 (0.60) | JAK2CCR6CCNA2CDK2 | |
| SCHEMBL32670637 | 0.79 | CCR6 (0.46) | JAK2CCR6LMNAIKBKBLRRK2 | |
| SCHEMBL25079898 | 0.78 | CCR6 (0.68) | CCR6CCNA2CDK2 | |
| SCHEMBL25079907 | 0.74 | CCR6 (0.52) | JAK2CNR1CCR6CCNA2CDK2 | |
| SCHEMBL32670381 | 0.74 | USP5 (0.55) | CCR6LMNATP53 | |
| SCHEMBL26461300 | 0.74 | CCR6 (0.59) | JAK2CCR6CCNA2CDK2 | |
| SCHEMBL31155684 | 0.73 | DYRK1A (0.42) | JAK2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | claimed |
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | JAK2 898/4885FPR2 235/4885PROKR1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.